Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

875
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
875
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

672
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
672
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

579
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
579
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

588
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
588
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

328
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumab.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

GETECCU: a comprehensive national strategy for excellence in inflammatory bowel disease.

Therapeutic advances in gastroenterology·2026
Same author

Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.

Medicina (Kaunas, Lithuania)·2025
Same author

Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry.

United European gastroenterology journal·2025
Same author

Plasma protein glycosylation: a biomarker for predicting metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.

Revista espanola de enfermedades digestivas·2025
Same author

Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST Study.

United European gastroenterology journal·2025

Related Experiment Video

Updated: Mar 7, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

561

Biosimilars in inflammatory bowel disease.

Carla J Gargallo1,2, Alberto Lué1,2, Fernando Gomollón3,2,4,5

  • 1Department of Gastroenterology, "Lozano Blesa" Clinical University Hospital, Zaragoza, Spain.

Minerva Medica
|February 9, 2017
PubMed
Summary
This summary is machine-generated.

Biosimilars offer a cheaper alternative to biologics for inflammatory bowel disease (IBD). Current evidence suggests switching to infliximab biosimilars is safe and effective, but more data is needed for interchangeability.

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

561
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Biotechnology

Background:

  • Biologic therapies have transformed inflammatory bowel disease (IBD) treatment.
  • Biologics represent a significant cost in IBD management.
  • Biosimilars offer a more affordable alternative, potentially increasing therapy access.

Purpose of the Study:

  • To review the manufacturing and regulatory approval processes for biosimilars.
  • To examine the available evidence on approved biosimilars for IBD in Europe.
  • To address concerns regarding the efficacy and safety of biosimilars in IBD.

Main Methods:

  • Review of manufacturing processes for biosimilars.
  • Analysis of regulatory approval pathways in Europe.
  • Examination of published clinical evidence on infliximab biosimilars (CT-P13, SB2) in IBD.

Main Results:

  • Two infliximab biosimilars (CT-P13, SB2) are approved by the European Medicines Agency for all indications.
  • Available evidence indicates that switching from originator infliximab to biosimilars is feasible.
  • No significant differences in efficacy, immunogenicity, or safety have been observed post-switch.

Conclusions:

  • Switching to infliximab biosimilars in IBD appears safe and effective based on current data.
  • Experts recommend further evidence before considering infliximab biosimilars interchangeable with originators.
  • Continued research is crucial to fully establish the role of biosimilars in IBD therapy.